Research programme: peptide antibacterials - BayerAlternative Names: Peptide antibacterials research programme - Bayer; Research programme: TAN 1057 analogues - Bayer AG; TAN 1057 analogues research programme - Bayer AG
Latest Information Update: 25 Mar 2010
At a glance
- Originator Bayer
- Class Dipeptides
- Mechanism of Action Cell wall inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Gram-positive infections
Most Recent Events
- 18 Sep 2002 Preclinical trials in Gram-positive infections in Germany (unspecified route)